Finasteride Telehealth Providers and Pricing

Direct answer

RightFit now tracks standalone finasteride programs as well as compounded finasteride-containing combinations from Hims, Ro, Keeps, Happy Head, Mochi, Shed, and other providers. Standalone oral products, subscription pricing, topical combinations, and first-order promotions are stored separately. RightFit keeps FDA-approved standalone finasteride context distinct from compounded combinations and preserves each provider’s route, formula, term, and source.

Finasteride + minoxidil combinations

Men’s multi-ingredient products

The official finasteride label provides a clear single-ingredient reference

Current official labeling for PROPECIA identifies finasteride 1 mg as a prescription 5-alpha-reductase inhibitor indicated for male pattern hair loss in men. RightFit uses that label to establish the approved single-ingredient product context, not to define the status of compounded telehealth combinations.

This distinction lets the page say two things accurately at the same time: finasteride itself has an approved hair-loss product, while the compounded combinations currently tracked by RightFit are separate products with their own formulation and regulatory status.

Mochi currently publishes both oral and topical finasteride/minoxidil combinations

Mochi’s current telehealth catalog includes compounded oral finasteride plus minoxidil and a separate compounded topical finasteride plus minoxidil product. Both currently use a medication price plus a separate Mochi membership. RightFit keeps the oral and topical formulations as separate records even when their published medication prices are the same.

Route matters even when the ingredient pair is the same

An oral capsule and a topical serum are not the same product simply because both contain finasteride and minoxidil. Route, formulation, strength, excipients, provider instructions, and supply structure can differ. RightFit therefore treats route as part of product identity rather than a minor display detail.

Shed publishes several finasteride-containing compounded products

Shed’s current men’s hair catalog includes a topical minoxidil/finasteride serum, a three-ingredient oral tablet containing minoxidil, finasteride, and biotin, and a five-ingredient topical serum that adds tretinoin, vitamin E, and fluocinolone. Those are distinct formulations and should not be reduced to one finasteride price.

Several current Shed prices remain in review

RightFit has intentionally kept several Shed hair-pricing rows in review because the current provider pages display one starting or monthly amount near the top and a different monthly-equivalent amount in the billing section. Until those figures can be reconciled, RightFit can publish the product definition without publishing a disputed price.

A combination-product price is not a standalone finasteride price

When a telehealth provider sells finasteride only as part of a combination product, the published price belongs to that complete formulation. RightFit does not divide the price across ingredients or infer what the finasteride component would cost by itself. That would create a number the provider never published.

Membership and medication price should remain separate

Mochi’s current combination products use a medication price plus a separate membership. RightFit keeps those values separate so a change in membership can be tracked independently from a change in the product price. A reader can still understand the practical recurring structure without losing the original provider price.

Compounded combinations require separate regulatory wording

FDA states that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality. RightFit therefore does not describe a compounded finasteride/minoxidil product as an approved finasteride hair-loss drug simply because finasteride 1 mg has an approved standalone product.

Additional ingredients create a different product

A three-ingredient oral tablet and a five-ingredient topical serum should not be compared as though the only difference is price. The additional active ingredients, route, preparation type, and provider instructions create separate products. RightFit keeps those formulations under their own treatment slugs so their prices and sources remain traceable.

What to compare across finasteride-containing programs

• Standalone finasteride versus combination product.
• Oral versus topical route.
• Exact ingredient list when published.
• Compounded versus manufactured preparation type.
• Medication or program price when verified.
• Separate membership or recurring care fee.
• Supply period and billing cadence.
• Whether clinician access and shipping are included.
• Program-level state availability when verified.
• Provider-primary source and last-verification date.

What RightFit will not infer

• A combination-product price is not converted into a standalone finasteride price.
• A compounded combination does not inherit FDA approval from PROPECIA or another finasteride 1 mg tablet.
• A lower price does not establish better clinical value.
• An oral and topical combination are not treated as interchangeable.
• A disputed first-party price is not published simply because one displayed figure is lower.
• A provider regrowth claim is not adopted as an independent conclusion.
• Product strengths are not converted into individualized dosing advice.

Why approved-product context still matters

The official finasteride 1 mg label provides a useful regulatory anchor because it shows that finasteride has a defined approved hair-loss product and indication. That makes it easier to avoid two opposite errors: claiming finasteride has no approved hair-loss use at all, or treating every compounded finasteride-containing telehealth product as though it were the approved tablet.

Why source freshness matters

Hair telehealth providers can change formulas, ingredient strengths, plan terms, or billing language without changing the marketing name. RightFit therefore rechecks the current dedicated product page and keeps a verification date. If a formulation changes materially, the new offer should be represented as a changed product record rather than only a new price.

Questions a reader can use

• Is this standalone finasteride or a compounded combination?
• What other ingredients are in the product?
• Is it oral or topical?
• Is the price currently published or still in review?
• Is a separate membership required?
• Does the price cover one month or a longer supply?
• Are the provider’s billing figures internally consistent?
• Is this exact formulation verified in the relevant state?
• When was the source last checked?

What this comparison cannot decide

A public telehealth comparison cannot determine whether finasteride is appropriate for an individual, whether oral or topical treatment is preferable, or whether a combination product is suitable. Those are clinical decisions for a licensed healthcare professional. RightFit’s role is to keep the product, price, and regulatory distinctions clear.

Bottom line

Current RightFit data includes standalone oral finasteride from Hims, Ro, Keeps, and Happy Head alongside multiple compounded finasteride/minoxidil programs. Ro publishes quarterly finasteride at $20 per month effective, Hims starts at $22 per month, Happy Head publishes an $18 monthly equivalent on a six-month subscription, and Keeps separates standard from promotional three-month pricing. Combination products remain separate. across current plans.

Why the standalone approved product is a regulatory reference, not a price proxy

The approved finasteride 1 mg tablet establishes that a single-ingredient finasteride hair-loss product exists, but it does not provide the telehealth price of a compounded finasteride/minoxidil capsule or serum. RightFit therefore uses the official label for product-status context and the provider page for the commercial offer. The two sources answer different questions.

Why combination products need their own price history

If a provider changes the minoxidil amount, adds another ingredient, changes route, or revises the supply term, that can be a material product change rather than only a price change. RightFit should preserve the combination product’s own history instead of attaching every change to a generic finasteride record.

A complete finasteride-combination record keeps the ingredient list visible

For each current program, RightFit aims to preserve the exact formulation, route, compounded status, provider price or review state, required membership, supply and billing term, included services, source, and verification date. That structure prevents a multi-ingredient formula from being reduced to the price of one familiar ingredient.

This structure also prevents future standalone finasteride offers from being confused with the current combination-heavy dataset. If a provider publishes a verified finasteride-only product later, RightFit can add it as its own record without reinterpreting existing combination prices.

It also keeps standalone and combination finasteride trends independently auditable over time.